Fink-Jensen, Anders
Wörtwein, Gitta
Klausen, Mette Kruse
Holst, Jens Juul
Hartmann, Bolette
Thomsen, Morgan
Ptito, Maurice
Beierschmitt, Amy
Palmour, Roberta M.
Funding for this research was provided by:
Copenhagen University
Article History
Received: 12 March 2024
Accepted: 20 May 2024
First Online: 17 June 2024
Declarations
:
: AFJ has received two unrestricted research grants from Novo Nordisk A/S for two clinical studies investigating the effects of liraglutide (finished) and semaglutide (ongoing) in prediabetic schizophrenia patients on antipsychotic medication (Larsen et al. (2017), JAMA Psychiatry, 74(7):719–728) and (Reeberg Sass et al. (2023), BMJ Open, 13(1):e068652, respectively. BH is a board member and cofounder of Bainan Biotech. JJH has served on scientific advisory panels and/or speaker for Novo Nordisk, Eli Lilly, and Zealand Pharma. He has given lectures and received financial support for travel from Novo Nordisk, Novo Nordisk Pharma, Novo Nordisk Scandinavia AB, and Mayo Clinic. He has served as a consultant for Alphasights, Eli Lilly, Shouti/Structure Therapeutics X, and Zealand Pharma. JJH is currently consulting for GV Management L.L.C. He is cofounder and on the board of directors of Antag Therapeutics and Bainan Biotech and sits on the board of directors of Antag Therapeutics and Bainan Biotech, which is unpaid. JJH serves as an investigator for Boehringer Ingelheim and Scohia. The other authors declare no competing financial interests concerning the work described.